Young Investigator Prize to Anita Sveen during annual "Onkologisk Forum" meeting Nov 2017

Anita Sveen
Anita Sveen

Dr. Anita Sveen from Ragnhild Lothe's group at the Department of Molecular Oncology received the Young Investigator prize at Onkologisk Forum for her research accomplishments. This annual meeting for oncologists took place in Oslo on November 16-17. The award amounts to 50.000 NOK, to be spent on research.

Sveen presented her research in computational oncology, focusing on clinical relevant questions for colorectal cancer and novel results published in 6 selected papers.


Dr. Jarle Bruun's research profiled in the 2016 National report from the Health Regional Authorities


The report highlights clinically relevant research and projects ongoing in the KG Jebsen Colorectal cancer research centre was selected from the Health Region South East. Specifically, Dr Jarle Bruun's paper identifying the gene Regulator of chromosome condensation 2 (RCC2) as functionally important in colorectal cancer, and furthermore that changes of RCC2 at the DNA and protein level can identify clinically distinct subgroups of patients with inferior survival. This is the first paper that reports clinical relevance of RCC2 in cancer. Bruun has already contributed to two ongoing innovation projects from the Lothe group at the Department of Molecular Oncology, Institute for Cancer Research.

Forskning og innovasjon til pasientens beste - Nasjonal rapport fra spesialisthelsetjenesten 2016


Three master's students graduated from the Department of Molecular Oncology




From left to right:

MSc Marthe Norreen Thorsen
The title of thesis:  "Functional evaluation of polo like kinase 1 (PLK1), a potential drug target, in malignant peripheral nerve sheath tumor cells"
Supervisors: Matthias Kolberg, Edward Leithe, and Ragnhild A. Lothe

MSc Mariella Evelyn Güere
The title of thesis:  "Identification of DNA methylation biomarkers for gastrointestinal cancer - Ubiquitin C-terminal hydrolase L1 (UCHL1)"
Supervisors: Hege Marie Vedeld and Guro E. Lind

MSc Kristina Totland Carm
The title of thesis:  "Investigation of DNA and RNA changes in multifocal prostate cancer - Identification of novel alterations and molecular subtyping of individual tumors"
Supervisors: Marte Løvf, Rolf Skotheim, and Ragnhild A. Lothe


Epigenetic markers stratify colorectal cancer patients within a genetically defined poor prognostic patient group

Hege Marie Vedeld og Marianne Merok.
Hege Marie Vedeld og Marianne Merok.

Vedeld and co-workers show that the CpG Island Methylator Phenotype (CIMP) carry prognostic value across stages. Patients with microsatellite stable tumors with BRAF V600E mutations, defining a poor prognostic subgroup, can be further subdivided by the CIMP status. This is a study from the Lind and Lothe groups in collaboration with the clinical research team of Arild Nesbakken.


Identified potent drugs for MPNST

Matthias Kolberg og Jarle Bruun.

MPNST is a rare and aggressive soft tissue cancer, and no clinically tested drugs have so far demonstrated any benefit on survival for this patient group. In a collaborative study between the Lothe group and the Kallioniemi group at Finnish Institute for Molecular Medicine published in Molecular Oncology, scientists Matthias Kolberg and Jarle Bruun identified PLK1 and gemcitabine as potent drugs for MPNST. A library of more than 300 approved and investigational oncology compounds was screened by drug sensitivity and resistance testing (DSRT) across seven MPNST cell lines, two cultures of normal Schwann cells, and normal bone marrow cells, and the MPNST cells were found to be more sensitive towards PLK1 inhibitors and gemcitabine than the normal cells. The putative drug targets PLK1 and RRM1/RRM2 were also found to be overexpressed in MPNST cell lines compared to normal Schwann cells, as well as in MPNST patient material as compared to benign neuroectodermal tissue. The results point at new treatment strategies that should be evaluated in clinical trials.


Clinically important genetic heterogeneity in colorectal cancers with microsatellite instability

First authors Anita Sveen, Torstein Tengs and Bjarne Johannessen (contributed equally)
First authors Anita Sveen, Torstein Tengs and Bjarne Johannessen (contributed equally)

Microsatellite instability (MSI) defines a small subgroup of approximately 15% of colorectal cancers (CRC) which currently receives much attention due to its overall good response to immune-checkpoint inhibition. In the latest issue of Genome Medicine, scientist Anita Sveen and colleagues publish the largest multilevel genetic analysis of this tumor type reported to date, describing substantial inter- and intra-tumor heterogeneity. The clinical importance of these results, in particular with respect to the optimized use of immunotherapeutics for treatment of human cancers, was emphasized in a Research Highlight in the same issue of the journal.


Innovation project from the Lind group featured by GenomeWeb


The New York based news organization GenomeWeb recently presented an in-depth article about the Oslo University Hospital-efforts of developing a urine-based test for monitoring of bladder cancer patients. Professor Guro Lind presented the project at the Oslo Life Science Conference 2017 previously this year (watch presentation, 58 minutes into the recording. The project drew the attention of Bjarne Røsjø in Titan and was later picked up by GenomeWeb.


New PhD, Marianne L. Smebye, found RNA changes involved in ovarian cancer

Marianne L. Smebye
Marianne L. Smebye

As part of a long-term collaboration between the Section for Cancer Cytogenetics at the Institute for Medical Informatics and Section for Molecular Oncology at the Institute for Cancer Research, a joint PhD project has been carried out to study RNA changes in ovarian cancer.

The PhD work concluded on March 17th, when Cand. med. Marianne Lislerud Smebye successfully defended her thesis "Transcriptomic consequences of chromosome 19 rearrangements in ovarian carcinomas" for the PhD degree. The same day, she held an excellent trial lecture over the given topic "Chromosomal abnormalities and copy number rearrangements as clinical targets in cancer". The PhD work was jointly surpervised between Francesca Micci (main supervisor), Sverre Heim and Rolf Skotheim.


A retrospective pooled biomarker study to predict overall survival beyond the TNM system

Researchers Stine Aske Danielsen and Anita Sveen.
Researchers Stine Aske Danielsen and Anita Sveen.

K.G.Jebsen Colorectal Cancer Research Centre scientists participated with data from patients admitted to OUH in a multicenter study of >7000 stage II and III CRC recently reported in Annals of Oncology (Dienstmann et al).
Incorporation of MSI, BRAFV600E and KRAS mutation status to overall survival models with TNM staging improves the ability to precisely prognosticate in stage II and III CC patients, but only modestly increases prediction accuracy in multivariable models that include clinicopathological features, particularly in chemotherapy-treated patients.


POLE proofreading domain mutations identify a subset of immunogenic colorectal cancers with excellent prognosis

Ragnhild A. Lothe and Arild Nesbakken
Ragnhild A. Lothe and Arild Nesbakken

A multicentre biomarker study, including data from the research teams of professors Ragnhild A. Lothe and Arild Nesbakken at the K.G.Jebsen Colorectal Cancer Research Centre, OUH, was recently published in Lancet Gastroenterology & Hepatology.
A small subgroup of patients with exceptionally mutated (ultramutated) cancers caused by mutations that impair DNA polymerase epsilon (POLE) proofreading are shown to have excellent prognosis.

Previous news
 The Norwegian Cancer Society calls attention to collaborative study on relevance of genetic heterogeneity  
 Clinical relevance of genetic heterogeneity among distinct liver metastatic deposits identified in patients with colorectal cancer  
 Article on colorectal cancer research at  
 Post doc Jarle Bruun awarded excellent article from Oslo University Hospital for the second half of 2015  
 National conference on clinical genomics Losby III 10.-11. mars 2016 
 Ragnhild A. Lothe and Michael Bretthauer substantially supported by FRIPRO  
 New PhD Andreas Hoff publishes testis cancer fusion genes in Cancer Research  
 Ragnar Mørk legacy prize 2015 to Guro E. Lind Ceremony Friday November 20th 
 Group leader Guro E. Lind appointed leader of the newly established Young Academy of Norway  
 Review article in Oncogene on alternative splicing in cancer  
 Personalized cancer medicine. Chronicle in the Norwegian newspaper, Aftenposten  
 Interview in weekly magazine on big data in cancer biomedicine  
 Cover article on personalized cancer medicine and big data in META  
 Many OUS teams in the Holmenkollstafetten 2015 Public health improvement: 
 Novel DNA methylation biomarkers provide accurate detection of bile duct cancer  
 Supercomputing reveals the genetic code of cancer Rolf Skotheim interview in Apollon: 
 Masterstudent Heidi Pharo graduated from the Department of Cancer Prevention  
 New comprehensive review on PI3K signaling in colorectal cancer  
 SMART Colorectal Cancer featured in Norwegian patient safety publication  
 Movember: Team Cancer Prevention  
 Oslo University Hospital awarding excellent research  
 Official opening of the KG Jebsen Colorectal Cancer Research Centre  
 Department of Cancer Prevention held a public cancer research event for the Røst community  
 Two new PhDs  
 Marthe Løvf defended her thesis for the PhD degree  
 Successful cancer genomics conference at Losby followed up by national media  
 New K.G. Jebsen Center for colorectal cancer research led by Ragnhild A. Lothe  
 Bioinformatician Torfinn Nome defending PhD thesis on deep RNA sequencing of colorectal cancer  
 Comprehensive review free online  
 Publication in Nature Genetics on testicular cancer susceptibility  
 PhD student Deeqa Ahmed profiled in Uniforum  
 Research based innovation  
 Comprehensive review on molecular biology of germ cell tumors of the ovary  
 Group leader Guro E. Lind invited to Ekko, NRK P2  
 Ragnhild A. Lothe appointed "Innovator of the month" by Helse Sør-Øst for March 2013  
 Alagaratnam article published in Stem Cells and Development  
 Breaking advances in prognostic testing of colorectal cancer  
 New group in Epigenetics established at the Institute for Cancer Research, Dept of Cancer Prevention  
 Ragnhild A. Lothe selected Scientist of the Month  
 ColoGuideEx receives attention  
 Anita Sveen and Trude Holmeide Ågesen successfully defended their PhD theses  
 British biotech company signs agreement with Inven2 to secure exclusive rights to biomarkers identified in the Lothe group  
 New gene-based prognostic test for colorectal cancer  
 The Norwegian Oncology Forum’s Young Researcher award 2011 to Guro E. Lind  
 Stine Aske Danielsen successfully defends her PhD thesis  
 Andreas Hoff and Peter Eide awarded Master’s degree  
 Researchers from Department of Cancer Prevention reveal importance for transcriptome instability in colorectal cancer  
 Ragnhild A. Lothe elected to the EACR Council  
 Marianne Berg - Excellent trial lecture for PhD  
 Maren Høland graduated  
 Forskning om nerveskjedesvulster omtalt på forskningsrådets hjemmeside  
 Translational research on colorectal cancer within Oslo University hospital featured in Dagbladet newspaper  
 Molecular Genetics group publishes in Journal of Clinical Oncology  
 MSc degree to Anne Cathrine Bakken  
 Dr. Ragnar Mørk legacy prize 2009 to Rolf I. Skotheim  
 The biomarker project in Aftenposten  
 Interview with Guro Lind in Apollon  
 Disputation and trial lecture - Terje Cruickshank Ahlquist  
 Stine Danielsen awarded poster prize at the 30th Scandinavian Sarcoma Group Meeting  
 Mutations in the Neurofibromin gene, an inhibitor of KRAS  
 New microarray design for detection of fusion genes  
 Ahlquist and colleagues identify time of occurrence of specific methylation events in colorectal development.  
 Marthe Eken graduated  
 Interview with Ragnhild Lothe on national television [in Norwegian]  
 Skotheim - First runner up to Idea Prize 2008  
 Young Investigator Award to Rolf Skotheim  
 Invited speaker at Biomarker Discovery Conference  
 Dietary effects on genes - National Broadcasting Company  
 In thin air - The annual mountain trip  
 ”Signaling in colorectal cancer”. Two recent papers by PhD students Stine A. Danielsen and Terje Ahlquist and colleagues  
 On the road again  
 Interview with Guro E. Lind in Universitas  
 Cancer Prevention - on thin ice...  
 State visit to Portugal, May 2008.  
 Master student Hilde Honne graduated  
 Masterstudenter intervjuet  
 What is epigentics? - National Broadcasting Company  
 Medinnova Idea Prize 2007 - presentation in Onkonytt  
 Rolf I. Skotheim appointed visiting professor in Finland  
 Medinnova's Idea Prize to research group working on early markers for tumors in the digestive system  
 Edgar Rivedal elected member of scientific council of IARC  
 Ragnhild A Lothe awarded the "King Olav V's Cancer Research Award"  
 King Olav V’s prize for cancer research 2007 awarded to Ragnhild A. Lothe  
 Center for Cancer Biomedicine funded  
 New cancer review journal edited at RR-Medical Centre: Critical Reviews in Oncogenesis  
 Porto – Oslo collaboration publishes improved prognostication by genetic analyses of prostate cancer  
 CoE-applicant from the Institute for cancer research to final round  
 New Department  
 Lothe group participant in a new Centre of Sciencebased Innovation  
 New data from an international collaborative study on TP53 and colorectal cancer, including data from the Lothe lab  
 Kristine Kleivi interviewed by the Norwegian Cancer Society  
 Ragnhild Lothe new member of the Commission for Forensic Medicine  
 Funding provided by Helse Sør  
 Disputation and trial lecture - Kristine Kleivi  
 Disputation and trial lecture - Guro E. Lind  
 Cover article in Neoplasia by Lin Thorstensen and coworkers. February 2005.  
 Ragnhild Lothe's group supported from National Cancer Plan